[PDF] Top 20 A_SUPUESTO 13 - Monitorio y Ejecución
Has 10000 "A_SUPUESTO 13 - Monitorio y Ejecución" found on our website. Below are the top 20 most common "A_SUPUESTO 13 - Monitorio y Ejecución".
Effects of erlotinib therapy on [11C]erlotinib uptake in EGFR mutated, advanced NSCLC
... TKI uptake after disease progression appears, and consequently, may aid in deciding whether or not to discontinue EGFR TKI ...the effects caused by the presence of therapeutic concentra- tions of ... See full document
10
Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [11C]erlotinib PET
... Specific EGFR TKIs, such as gefitinib and erlotinib, gained FDA approval for the treatment of advanced NSCLC in 2003 and 2004, ...of NSCLC patients ...the EGFR mutational status ... See full document
115
<p>Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial</p>
... for EGFR- mutant advanced NSCLC. However, whether EGFR-TKIs are effective as adjuvant chemotherapy in EGFR-mutant early-stage NSCLC has yet to be ...adjuvant erlotinib in ... See full document
14
Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats
... of erlotinib [7]. Erlotinib is mainly eliminated through hepatobiliary clearance and undergoes hepatic metabolism by cytochrome P450 (CYP) 3A4/3A5 and, to a lesser extent, by CYP1A1/2 ...affect ... See full document
6
<p>Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer</p>
... with EGFR-muta- tion-positive stage II-IIIA NSCLC, who were randomly assigned, at a 1:1 ratio, into targeted therapy and che- motherapy ...targeted therapy groups received Ge fi tinib 250 mg/d ... See full document
7
Mechanisms of resistance to ErbB targeted cancer therapeutics
... the EGFR- targeted TKI erlotinib and the EGFR-tar- geted monoclonal antibody cetuximab, suggesting that loss of IGFBPs is involved in resistance to other ErbB-targeting TKIs and ...ErbB-targeted ... See full document
99
Erlotinib in the treatment of advanced pancreatic cancer
... therapeutic EGFR inhibition have been developed: monoclonal antibodies (mAbs) that bind to the extracellular domain of EGFR, and TKIs that inhibit the intracellular tyrosine kinase ...of EGFR, ... See full document
104
Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
... The AUC model calculates the likelihood of patients remaining in either progression-free survival or overall sur- vival without discrete transitions using individual parametric survival curves fitted to the Kaplan–Meier ... See full document
5
Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
... had advanced NSCLC previously treated with first-line therapy and all histologies were ...side effects of pemetrexed, such as anemia, fatigue, nausea, vomiting, were reduced in the arm ... See full document
62
Update on nonsmall cell lung cancer
... IV NSCLC patients, and showed that the four regimens were somehow equivalent in terms of OS, reaching a plateau of 8 months of median survival, with 30–35% patients surviving to 1 ...in NSCLC was ... See full document
8
EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR TKI
... with EGFR-tyrosine kinase in- hibitors ...the EGFR gene were associated with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with ...the EGFR gene were evaluated in 71 ... See full document
59
EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models
... generation EGFR-TKIs demonstrated significant clinical response in patients with tumors driven by EGFR-TKI sensitizing mutations ...the EGFR kinase ...mutant EGFR and causes steric ... See full document
58
<p>Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date</p>
... Targeted therapies have profoundly modi fi ed the prognoses of lung cancers with onco- genic mutations, achieving notably improved progression-free (PFS) and overall survival (OS) rates compared to reference chemotherapy ... See full document
15
Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
... radiation therapy, recent advances in understanding of NSCLC biology and immunology have spurred the development of numerous targeted ...of advanced NSCLC patients, potentially heralding the ... See full document
7
Review Article Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors
... the EGFR family members, only tyrosine-phosphorylated HER3 directly binds to p85 via the SH2 domain of ...the EGFR family members, only HER3 has this ... See full document
63
Original Article Overcoming Taxol resistance through the inhibition of EGFR-mediated glucose metabolism in oral cancer cells
... the effects of combining Taxol with glycolysis inhibitors on Taxol-resistant breast cancer ...blocking EGFR signaling pathway together with glucose metabolism inhibitors significantly inhibited the ... See full document
154
Targeted therapy for localized non-small-cell lung cancer: a review
... The International Tailored Chemotherapy Adjuvant (ITACA) trial is a Phase III biomarker study using tumoral ERCC1 and thymidylate synthase (TS) messenger RNA expression levels to guide treatment decisions. Patients with ... See full document
6
CRIPTO1 expression in EGFR mutant NSCLC elicits intrinsic EGFR inhibitor resistance
... harbor EGFR-activating mutations that can be therapeutically targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI), such as erlotinib and ...with EGFR mutations are refractory to ... See full document
5
Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer
... Personalized therapy of advanced non-small cell lung cancer (NSCLC) has been improved by the introduction of EGFR tyrosine kinase inhibitors (TKIs), gefitinib and ...erlotinib. ... See full document
5
Personalized medicine and treatment approaches in non-small-cell lung carcinoma
... the EGFR gene, further personalization of treatment for subgroups of patients has become a ...and EGFR mutations, EML4/ALK translocation, and ERCC1 (excision repair cross-complementing 1) and EGFR ... See full document
7
Related subjects